Svanström H, et al. - Using data from nationwide registers in Denmark and Sweden for from January 1, 2010, to December 31, 2016, researchers examined the risk of major cardiovascular events correlated with use of liraglutide vs an active comparator drug class, dipeptidyl peptidase-4 (DPP-4) inhibitors, in patients with type 2 diabetes in routine clinical practice. The cohort included incident users of liraglutide or DPP-4 inhibitors, who also used baseline metformin, matched 1:1 based on age, sex, and propensity. Among 23,402 users of liraglutide and 23,402 matched users of DPP-4 inhibitors, a major cardiovascular event occurred in 1,132 users of liraglutide. Findings revealed that the use of liraglutide was related to a significantly lower risk of major cardiovascular events vs the use of DPP-4 inhibitors. Patients with a history of cardiovascular disease seemed to benefit most from liraglutide treatment. In routine clinical practice, these data provide support for the cardiovascular efficacy of liraglutide.